<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: We report on a patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> infantile neurological cutaneous and articular (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>) syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Sequence analysis revealed a novel missense mutation in exon 4 of the CIAS1 gene </plain></SENT>
<SENT sid="2" pm="."><plain>The patient was unresponsive to several treatments including <z:chebi fb="2" ids="8378">prednisolone</z:chebi>, <z:chebi fb="1" ids="35705">immunosuppressants</z:chebi> (<z:chebi fb="2" ids="2948">azathioprine</z:chebi> and cyclosporin), disease-modifying <z:chebi fb="0" ids="35842">antirheumatic drugs</z:chebi> (DMARDs: <z:chebi fb="0" ids="50868,7959">penicillamine</z:chebi>, salazopyrin and <z:chebi fb="0" ids="44185">methotrexate</z:chebi>) and the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-a)-blocker infliximab </plain></SENT>
<SENT sid="3" pm="."><plain>At 32 mo of age, administration of the recombinant human interleukin-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> anakinra commenced, which caused an immediate and marked improvement in the clinical symptoms and laboratory test results </plain></SENT>
<SENT sid="4" pm="."><plain>Continuous inhibition of the <z:mp ids='MP_0001845'>inflammation</z:mp> required a dose of 1.0 mg/kg every 12 h </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Following the diagnosis of <z:e sem="disease" ids="C0409818" disease_type="Disease or Syndrome" abbrv="CINCA">CINCA syndrome</z:e>, anakinra treatment should be commenced as the first line of therapy </plain></SENT>
</text></document>